In conclusion, our results showed that SLMO2 expression was significantly up-regulated in tumors and was closely related to immune infiltration and tumors’ proliferation and migration, providing research basis and support for SLMO2 regarding as a potential therapeutic and prognostic biomarker for cancers. This evidence concerns the gene PRELID3B and cancer.